Pharmaceuticals

Emalex Biosciences offers its investigational drug ecopipam to Tourette syndrome patients out of options, signaling a potential shift in treatment.

A massive investment in Kankakee promises hundreds of jobs and a vital increase in life-saving plasma therapies for patients with rare diseases.

With 8x sales growth and 90% prediction accuracy, AI pioneer QuantHealth is proving that simulating clinical trials can slash pharma's $50B failure rate.

A new, highly selective drug for Duchenne muscular dystrophy shows potential to be safer and more effective, targeting both muscle and heart decline.

A landmark European approval for Elfabrio allows stable Fabry disease patients to switch to monthly infusions, promising greater freedom and lower healthcare strain.

A new drug, CRS3123, not only cures C. difficile but drastically cuts recurrence rates by preserving the gut microbiome, a major leap over standard care.

A new AI platform promises to solve the toxicology industry's capacity crisis, but can it win the trust of regulators and the scientists it’s meant to help?

Medicus Pharma's microneedle patch for basal cell carcinoma clears nearly three-quarters of lesions, offering a potential non-surgical alternative to the scalpel.

With new data on CUE-401, a novel therapy inspired by Nobel-winning science, Cue Biopharma makes a high-stakes play to redefine autoimmune treatment.

Founded by Emma Heming Willis, Make Time Wellness unveils three new products, tapping into a booming market with science-backed solutions for women's brain health.

With one trial halted and another beginning, the company focuses its cash and hopes on BBI-940, a novel drug targeting a fundamental driver of cancer.

UK's Abselion opens a US base in Cambridge, MA, aiming to disrupt biologics R&D with its rapid Amperia protein quantification system.

IDEAYA Biosciences begins a key trial for its targeted therapy IDE892, aiming to conquer hard-to-treat tumors and pivoting to focus on its proprietary assets.

With its runway extended by insiders, the biotech firm bets on its promising glioblastoma drug and an unconventional strategy of crypto and acquisitions.

Early access programs for a rare blindness therapy in France, Israel, and the US offer hope to patients and provide a crucial financial lifeline for the company.

A new trial in China tests a dual-action antibody for esophageal cancer, a top killer. The therapy aims to unleash a two-pronged immune attack on tumors.

Amid rising avian flu concerns, Canada secures millions of next-gen cell-based vaccines, upgrading its pandemic response arsenal for faster protection.

Eli Lilly and the WHO Foundation have launched a new collaboration to strengthen health systems and combat the escalating obesity crisis in underserved regions.

French pharma giant Servier acquires Day One Biopharmaceuticals, gaining a breakthrough pediatric cancer drug and signaling a major push into rare oncology.

Atlas Health's new AI agent, Ava, aims to tackle the healthcare affordability crisis by automating access to financial assistance programs.